1. Lenis, A.T., Lec, P.M., and Chamie, K., Bladder cancer: a review, JAMA, 2020, vol. 324, no. 19, pp. 1980–1991.
2. Karpin A.D., Starinsky V.V., and Shakhzadova A.O., Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2020 godu (The State of Oncological Care for the Population of Russia in 2020), 2021.
3. Cao, Y. et al., Phase I study of gemcitabine–cisplatin versus pemetrexed–cisplatin for patients with advanced or metastatic bladder cancer, JBUON, 2018, vol. 23, no. 2, pp. 475–481.
4. Saiki, Y., Hirota, S., and Horii, A., Attempts to remodel the pathways of gemcitabine metabolism: recent approaches to overcoming tumours with acquired chemoresistance, Cancer Drug Resistance, OAE Publishing Inc., 2020, vol. 3, no. 4, pp. 819–831.
5. Wong, A., Soo, R.A., Yong, W.P., and Innocenti, F., Clinical pharmacology and pharmacogenetics of gemcitabine, Drug Metabolism Rev., 2009, vol. 41, no. 2, pp. 77–88.